Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus Irinotecan in EGFR-detectable Metastatic Colorectal Carcinoma
NCT00362102Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2005
- Primary completion
- Jul 2006
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in colorectal cancer (CRC), sponsored by Eli Lilly and Company. Primary endpoint: Objective Response Rate. Started Oct 2005; status: completed.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00362102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00362102.